The antioxidant capacity of the glutathione redox cycle and the concentrations ofselenium in serum, red blood ceils or whole blood, and polymorphonuclear leucocytes was evaluated in nine patients with severe rheumatoid arthritis (RA) and eight healthy controls receiving daily supplementation with 250 jg selenomethionine for six months. Serum and whole blood concentrations of selenium and the activity of the selenium dependent enzyme glutathione peroxidase (GSH-Px) were low in the serum, red blood cells, and polymorphonuclear leucocytes ofpatients with RA before selenium supplementation. During supplementation serum and whole blood concentrations of selenium and the activity of GSH-Px in serum and red blood cells of patients with RA and serum GSH-Px in controls increased. Selenium and GSH-Px in polymorphonuclear leucocytes were unaffected in patients with RA in contrast with the controls where both were augmented. Glutathione reductase activity in the red blood cells and polymorphonuclear leucocytes of patients with RA was low but increased during selenium supplementation. Whole blood concentrations of glutathione were slightly lower in patients with RA than controls and no difference in the content in polymorphonuclear leucocytes was found between the groups. The activity in red blood cells of glucose-6-phosphate dehydrogenase was high in patients with RA, indicating sufficient function of the hexose monophosphate pathway. The reduced antioxidant activity of the glutathione redox cycle in patients with severe RA was mainly due to the low availability of selenium. This was further supported by the response to selenium supplementation in serum and red blood ceils. In the polymorphonuclear leucocytes, however, no biochemical effects of selenium supplementation were seen. This lack of antioxidative response could play a pathogenetic part in inflammation in patients with RA.
Abstract
The antioxidant capacity of the glutathione redox cycle and the concentrations ofselenium in serum, red blood ceils or whole blood, and polymorphonuclear leucocytes was evaluated in nine patients with severe rheumatoid arthritis (RA) and eight healthy controls receiving daily supplementation with 250 jg selenomethionine for six months. Serum and whole blood concentrations of selenium and the activity of the selenium dependent enzyme glutathione peroxidase (GSH-Px) were low in the serum, red blood cells, and polymorphonuclear leucocytes ofpatients with RA before selenium supplementation. During supplementation serum and whole blood concentrations of selenium and the activity of GSH-Px in serum and red blood cells of patients with RA and serum GSH-Px in controls increased. Selenium and GSH-Px in polymorphonuclear leucocytes were unaffected in patients with RA in contrast with the controls where both were augmented. Glutathione reductase activity in the red blood cells and polymorphonuclear leucocytes of patients with RA was low but increased during selenium supplementation. Whole blood concentrations of glutathione were slightly lower in patients with RA than controls and no difference in the content in polymorphonuclear leucocytes was found between the groups. The activity in red blood cells of glucose-6-phosphate dehydrogenase was high in patients with RA, indicating sufficient function of the hexose monophosphate pathway. The Reports disagree as to whether the levels of the selenium dependent enzyme glutathione peroxidase (GSH-Px) are reduced,' normal,7-9 or even increased'0 in RA. The disagreement may originate in the variability of the patients studied." A low selenium level in the serum and red blood cells of patients with RA has been reported in areas of relatively low and high natural dietary selenium intake.'2'6 Selenium supplementation within a nutritional range has been shown to increase the concentration of selenium in serum and red blood cells and to stimulate GSH-Px in serum and red blood cells but not in polymorphonuclear leucocytes. 4 The glutathione redox cycle is part of the defence against the toxicity induced by free oxygen radicals. The cycle comprises glutathione (the tripeptide y-glutamylcysteinylglycine) and the enzymes GSH-Px and glutathione reductase (GSSG-R). The system is coupled to the hexose monophosphate pathway by NADP (nicotinamide adenine dinucleotide phosphate), which is used in the glutathione reductase reaction (fig 1) . The net result of the cycle reaction is the reductive capacity of GSH-Px, which catabolises hydrogen peroxide and organic peroxides into non-toxic compounds.
The aim of this study was to evaluate the antioxidative capacity of the entire glutathione redox cycle and relate this to the concentrations of selenium in serum, red blood cells, and polymorphonuclear leucocytes before and during six months of supplementation with selenium.
Patients and methods

PATIENTS AND CONTROLS
The study included nine patients with severe active RA selected on the following criteria: glucose-6-phosphate dehydrogenase (G-6-PD) were frozen at -60°C. These analyses were carried out within one week of collection. Repetition of assays in red blood cells and serum samples showed that enzymatic activities remained stable for at least four weeks. The samples for the determination of selenium were frozen at -60°C until analysis. All analyses except the particle induced x-ray emission (PIXE) analyses were performed in duplicate. Reduced glutathione was determined by the method of Beutler et al."7 Fresh whole blood (0-2 ml) or 0 4 ml polymorphonuclear leucocyte homogenate was diluted with 1 8 ml distilled water and mixed with 3 ml of a precipitating solution (1 67 g metaphosphoric acid, 0-2 g EDTA(Na2), and 30 g NaCl in 100 ml water). After filtration 2 ml filtrate, 8 
STATISTICS
The results were processed by analysis of variance using the SPSS/PC+ program package. The variables were initially examined graphically to confir the presence ofa normal distribution. The assumption of variance homogeneity was tested by Bardett's test. A logarithmic transformation was used to stabilise the variances with respect to the selenium concentration data. Multivariate MANOVA (repeated measures) was used to test the effects of time on the biochemical variables among the patients with RA and the control group as well as the time (17) tig/l v 89 (12) [tg/l; whole blood selenium 95 (14) ,ug/l v 125 (13) [tg/l).
During supplementation a significant increase was seen, reaching a level that did not vary significantly between the groups (figs 2 and 3).
No plateau was reached in serum or whole blood samples for the patients with RA, contrary to the controls who reached a plateau after three months. Selenium in polymorphonuclear leucocytes was significantly lower in the patients with RA than in the controls. Bexore supplementation no difference was found between the groups. Selenium supplementation did not affect the selenium level in polymorphonuclear leucocytes in the patients with RA but caused a significant increase in the controls (fig 4) . The patients with RA had a significantly lower serum GSH-Px activity level than the controls before supplementation but the two groups experienced a significant increase during supplementation and after six months no difference was seen (table 1 and fig 2) . GSH-Px activity in red blood cells was significantly lower in the patients with RA before supplementation and selenium supplementation increased the activity in patients with RA to a level not different from the controls. In the controls no changes were seen during supplementation (table 1 and fig 3) . GSH fig 4) .
GSSG-R activity in red blood cells was significantly lower in the patients with RA than in the controls before supplementation. Supplementation increased the activity in patients with RA to a level significantly above that of the controls, whereas no changes were seen in the control group (table 2) . GSSG-R in polymorphonuclear leucocytes did not differ significantly between the groups although the level tended to be lower in the patients with RA before supplementation and after three months (MANOVA, repeated measures; p=0 13) . During supplementation a significant increase was seen in the rheumatoid arthritis group and the level tended to be higher than that of the controls. No change was seen in the controls during supplementation (table 2) .
Glutathione concentrations in whole blood were slightly but not significantly lower in the patients with RA than in the controls (MANOVA, repeated measures; p=0 07). No significant differences between the groups were recorded before supplementation. Supplementation had no effect in either of the groups (table 3) . No significant differences were found among patients with RA and controls with respect to glutathione content in polymor- phonuclear leucocytes and no change in either of the groups was seen during supplementation (table 3) . G-6-PD in red blood cells was significantly higher in the patients with RA throughout the study. No difference between the groups was recorded before supplementation. No change was seen during supplementation in either of the groups (table 3) .
Discussion
The patients with RA in this study belong to a subset of patients with RA with persistently high disease activity who had not responded to conventional treatment with disease modifying drugs. The finding of low selenium concentrations in serum and whole blood samples agrees with previous data23 and may be interpreted as a response to arthritis activity.4 15 Selenium supplementation increased the selenium concentration in the serum and whole blood of patients with RA and controls and no significant differences were observed between the groups at the end of supplementation. Patients with RA had a reduced selenium concentration in polymorphonuclear leucocytes which was unaffected by selenium supplementation. This is in contrast to the increase found in the controls during supplementation and suggests that the selenium metabolism in active RA is affected in the polymorphonuclear leucocytes, probably as a result of the impaired uptake of selenium during the formation of cells in the bone marrow. Previously only one study has dealt with the content of selenium in polymorphonuclear leucocytes in patients with RA. Applying the nuclear microprobe PIXE technique to individual polymorphonuclear leucocytes Lindh and Johansson24 could only trace selenium in the polymorphonuclear leucocytes of the controls and not in the three patients with RA studied. Using the same technique selenium supplementation (200 ,ug selenite/day) was found to increase the content of selenium in polymorphonuclear leucocytes in one healthy subject. 25 The function of GSH-Px and thereby the net antioxidant capacity of the glutathione redox cycle is dependent on: (a) the available amount of selenium for de novo synthesis of GSH-Px; (b) the intracellular concentration of glutathione; (c) the activity of GSSG-R; and (d) the NADPH generation through hexose monophosphate pathway activity. In this study several components of the glutathione redox cycle were impaired before selenium supplementation.
The G-6-PD activity in red blood cells was significantly higher in the patients with RA than in the controls and no changes occurred during supplementation in either of the groups. The continuously high activity of G-6-PD despite increased GSH-Px/GSSG-R activity suggests that at least in the red blood cell the generation of NADPH is sufficient. In lymphocytes of patients with RA normal production of NAD+, NADH, NADP(H) and ATP has been found. 26 It may be assumed that similar conditions are found in the polymorphonuclear leucocytes, though we have no data to support it. Thus the low activity of GSH-Px and GSSG-R in red blood cells and polymorphonuclear leucocytes in patients with RA is likely to be explained by either a lack of glutathione or a low selenium level. The glutathione content in red blood cells and polymorphonuclear leucocytes was slightly lower, but no changes were observed when GSH-Px and GSSG-R activities increased. This suggests that the level of glutathione does not limit the glutathione cycle activity. GSSG-R is not a selenium dependent enzyme and the increase in red blood cells and polymorphonuclear leucocytes may be interpreted as a response to increased glutathione cycle activity mediated through GSH-Px. The polymorphonuclear leucocytes of the patients with RA showed a low activity of GSH-Px and the level of GSSG-R also tended to be low. Contrary to the enzyme activity in red blood cells and serum, selenium supplementation did not affect GSH-Px in polymorphonuclear leucocytes in patients with RA whereas an increase was seen in the polymorphonuclear leucocytes of the controls. This is in accordance with our previous findings,4 and may be explained by the insufficient increase in selenium in polymorphonuclear leucocytes leading to impaired de novo synthesis of GSH-Px. In the polymorphonuclear leucocytes of the controls a significant increase was found in selenium content and GSH-Px activity, which indicates that the enzyme is unsaturated at the presupplementation level in healthy subjects. In studies of patients developing selenium deficiency during parenteral nutrition the increase in GSH-Px in red blood cells and polymorphonuclear leucocytes has been found to be consistent with the kinetics of production of red blood cells and polymorphonuclear leucocytes. 27 Several studies have suggested a state of increased oxidative stress and reduced ability to resist attack by radicals in RA. 28 
